Introduction
Abrysvo is a bivalent RSV vaccine targeting both RSV A and RSV B subtypes, effectively preventing lower respiratory tract infections caused by Respiratory Syncytial Virus (RSV). Abrysvo has been approved for use in multiple countries including the United States, United Kingdom, Germany, Sweden, Australia, and others.
Recommended for
- Currently the only RSV vaccine in Hong Kong suitable for pregnant women at 32-36 weeks of gestation, providing maternal immunization to protect infants from RSV infection for up to 6 months after birth
- Adults aged 60 or above (including high-risk individuals with chronic conditions such as asthma, diabetes, or chronic obstructive pulmonary disease)
Dosage
- Only one dose is required
- Can be administered simultaneously with quadrivalent influenza vaccine or COVID-19 vaccine
Manufacturer
Pfizer